MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.440
+0.070
+5.11%
After Hours: 1.420 -0.02 -1.39% 16:45 11/27 EST
OPEN
1.380
PREV CLOSE
1.370
HIGH
1.440
LOW
1.370
VOLUME
592.01K
TURNOVER
--
52 WEEK HIGH
3.590
52 WEEK LOW
0.6200
MARKET CAP
84.70M
P/E (TTM)
-1.7555
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Benzinga's Top Upgrades, Downgrades For November 24, 2020
Upgrades * B of A Securities upgraded the previous rating for O-I Glass Inc (NYSE: OI) from Neutral to Buy. The current stock performance of O-I Glass shows a 52-week-high of 15.64 and a 52-week-low of 4.305. Moreover, at the end of the last trading period, the closing price was at $11.86. * Goldman Sachs upgraded the previous rating for Nutanix Inc (NASDAQ: NTNX) from Sell to Neutral. Nutanix earned $0.44 in the first quarter, compared to $0.71 in the year-ago quarter. The stock has a 52-week-high of 37.86 and a 52-week-low of 11.31. At the end of the last trading period, Nutanix closed at $28.47. * For General Electric Co (NYSE: GE), Oppenheimer upgraded the previous rating of Perform to the current rating Outperform. General Electric earned $0.06 in the third quarter, compared to $0.15 in the year-ago quarter. The current stock performance of General Electric shows a 52-week-high of 13.26 and a 52-week-low of 5.48. Moreover, at the end of the last trading period, the closing price was at $10.07. * According to B of A Securities, the prior rating for Domtar Corp (NYSE: UFS) was changed from Underperform to Neutral. For the third quarter, Domtar had an EPS of $0.33, compared to year-ago quarter EPS of $0.89. The stock has a 52-week-high of 40.05 and a 52-week-low of 18.4. At the end of the last trading period, Domtar closed at $30.27. * For AerCap Holdings NV (NYSE: AER), B of A Securities upgraded the previous rating of Neutral to the current rating Buy. In the third quarter, AerCap Holdings showed an EPS of $1.24, compared to $2.01 from the year-ago quarter. The current stock performance of AerCap Holdings shows a 52-week-high of 64.86 and a 52-week-low of 10.42. Moreover, at the end of the last trading period, the closing price was at $40.47. * According to Raymond James, the prior rating for Wells Fargo & Co (NYSE: WFC) was changed from Underperform to Outperform. In the third quarter, Wells Fargo showed an EPS of $0.42, compared to $1.07 from the year-ago quarter. The current stock performance of Wells Fargo shows a 52-week-high of 54.75 and a 52-week-low of 20.76. Moreover, at the end of the last trading period, the closing price was at $26.30. * According to Raymond James, the prior rating for Chubb Ltd (NYSE: CB) was changed from Outperform to Strong Buy. Chubb earned $2.00 in the third quarter, compared to $2.70 in the year-ago quarter. The current stock performance of Chubb shows a 52-week-high of 167.74 and a 52-week-low of 87.35. Moreover, at the end of the last trading period, the closing price was at $149.16. * For Ambarella Inc (NASDAQ: AMBA), Summit Insights Group upgraded the previous rating of Hold to the current rating Buy. Ambarella earned $0.09 in the third quarter, compared to $0.32 in the year-ago quarter. The current stock performance of Ambarella shows a 52-week-high of 73.59 and a 52-week-low of 36.02. Moreover, at the end of the last trading period, the closing price was at $66.37. Downgrades * According to Citigroup, the prior rating for Werner Enterprises Inc (NASDAQ: WERN) was changed from Buy to Neutral. In the third quarter, Werner Enterprises showed an EPS of $0.69, compared to $0.57 from the year-ago quarter. The stock has a 52-week-high of 47.43 and a 52-week-low of 28.99. At the end of the last trading period, Werner Enterprises closed at $40.32. * According to Deutsche Bank, the prior rating for ViacomCBS Inc (NASDAQ: VIAC) was changed from Buy to Hold. In the third quarter, ViacomCBS showed an EPS of $0.91, compared to $1.10 from the year-ago quarter. At the moment, the stock has a 52-week-high of 43.04 and a 52-week-low of 10.1. ViacomCBS closed at $34.62 at the end of the last trading period. * For Silgan Holdings Inc (NASDAQ: SLGN), B of A Securities downgraded the previous rating of Neutral to the current rating Underperform. Silgan Hldgs earned $1.04 in the third quarter, compared to $0.76 in the year-ago quarter. The current stock performance of Silgan Hldgs shows a 52-week-high of 40.44 and a 52-week-low of 24.645. Moreover, at the end of the last trading period, the closing price was at $34.58. * According to Citigroup, the prior rating for Schneider National Inc (NYSE: SNDR) was changed from Buy to Neutral. In the third quarter, Schneider National showed an EPS of $0.31, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of 28.13 and a 52-week-low of 15.36. At the end of the last trading period, Schneider National closed at $21.25. * Citigroup downgraded the previous rating for Knight-Swift Transportation Holdings Inc (NYSE: KNX) from Buy to Neutral. For the third quarter, Knight-Swift had an EPS of $0.79, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of 47.44 and a 52-week-low of 27.54. Knight-Swift closed at $40.96 at the end of the last trading period. * According to B of A Securities, the prior rating for Amcor PLC (NYSE: AMCR) was changed from Neutral to Underperform. For the first quarter, Amcor had an EPS of $0.16, compared to year-ago quarter EPS of $0.13. The stock has a 52-week-high of 12.4 and a 52-week-low of 5.8. At the end of the last trading period, Amcor closed at $11.57. * According to Jefferies, the prior rating for Ulta Beauty Inc (NASDAQ: ULTA) was changed from Buy to Hold. In the second quarter, Ulta Beauty showed an EPS of $0.73, compared to $2.72 from the year-ago quarter. The current stock performance of Ulta Beauty shows a 52-week-high of 304.65 and a 52-week-low of 124.05. Moreover, at the end of the last trading period, the closing price was at $282.87. * According to Deutsche Bank, the prior rating for PACCAR Inc (NASDAQ: PCAR) was changed from Buy to Hold. For the third quarter, PACCAR had an EPS of $1.11, compared to year-ago quarter EPS of $1.75. The current stock performance of PACCAR shows a 52-week-high of 95.82 and a 52-week-low of 49.11. Moreover, at the end of the last trading period, the closing price was at $89.56. * According to BTIG, the prior rating for Fulgent Genetics Inc (NASDAQ: FLGT) was changed from Buy to Neutral. In the third quarter, Fulgent Genetics showed an EPS of $2.08, compared to $0.14 from the year-ago quarter. The current stock performance of Fulgent Genetics shows a 52-week-high of 52.47 and a 52-week-low of 6.7. Moreover, at the end of the last trading period, the closing price was at $43.60. * Credit Suisse downgraded the previous rating for Baozun Inc (NASDAQ: BZUN) from Outperform to Neutral. In the third quarter, Baozun showed an EPS of $0.22, compared to $0.14 from the year-ago quarter. The current stock performance of Baozun shows a 52-week-high of 47.51 and a 52-week-low of 22.19. Moreover, at the end of the last trading period, the closing price was at $38.64. Initiations * With a current rating of Market Perform, BMO Capital initiated coverage on Southern Co (NYSE: SO). The price target seems to have been set at $67.00 for Southern. In the third quarter, Southern showed an EPS of $1.22, compared to $1.34 from the year-ago quarter. At the moment, the stock has a 52-week-high of 71.1 and a 52-week-low of 41.96. Southern closed at $60.44 at the end of the last trading period. * BMO Capital initiated coverage on Duke Energy Corp (NYSE: DUK) with an Outperform rating. The price target for Duke Energy is set to $99.00. In the third quarter, Duke Energy showed an EPS of $1.87, compared to $1.79 from the year-ago quarter. The stock has a 52-week-high of 103.79 and a 52-week-low of 62.13. At the end of the last trading period, Duke Energy closed at $93.34. * Berenberg initiated coverage on Cue Biopharma Inc (NASDAQ: CUE) with a Buy rating. The price target for Cue Biopharma is set to $30.00. For the third quarter, Cue Biopharma had an EPS of $0.34, compared to year-ago quarter EPS of $0.31. The stock has a 52-week-high of 31.69 and a 52-week-low of 9.3. At the end of the last trading period, Cue Biopharma closed at $12.01. * Berenberg initiated coverage on Black Diamond Therapeutics Inc (NASDAQ: BDTX) with a Buy rating. The price target for Black Diamond Therapeutic is set to $58.00. In the third quarter, Black Diamond Therapeutic showed an EPS of $0.50, compared to $4.50 from the year-ago quarter. At the moment, the stock has a 52-week-high of 46.25 and a 52-week-low of 17.63. Black Diamond Therapeutic closed at $33.54 at the end of the last trading period. * For Atea Pharmaceuticals Inc (NASDAQ: AVIR), William Blair initiated coverage, by setting the current rating at Outperform. At the moment, the stock has a 52-week-high of 34.81 and a 52-week-low of 31.5. Atea Pharmaceuticals closed at $33.54 at the end of the last trading period. * With a current rating of Buy, Berenberg initiated coverage on Arcus Biosciences Inc (NYSE: RCUS). The price target seems to have been set at $50.00 for Arcus Biosciences. In the third quarter, Arcus Biosciences showed an EPS of $0.03, compared to $0.51 from the year-ago quarter. The current stock performance of Arcus Biosciences shows a 52-week-high of 37.41 and a 52-week-low of 7.69. Moreover, at the end of the last trading period, the closing price was at $25.80. * With a current rating of Equal-Weight, Morgan Stanley initiated coverage on 2U Inc (NASDAQ: TWOU). The price target seems to have been set at $39.00 for 2U. 2U earned $0.24 in the third quarter, compared to $0.41 in the year-ago quarter. The stock has a 52-week-high of 49.46 and a 52-week-low of 11.51. At the end of the last trading period, 2U closed at $34.31. * HC Wainwright & Co. initiated coverage on Curis Inc (NASDAQ: CRIS) with a Buy rating. The price target for Curis is set to $5.00. Curis earned $0.11 in the third quarter, compared to $0.19 in the year-ago quarter. The current stock performance of Curis shows a 52-week-high of 3.59 and a 52-week-low of 0.62. Moreover, at the end of the last trading period, the closing price was at $1.35. * KeyBanc initiated coverage on Workday Inc (NASDAQ: WDAY) with an Overweight rating. The price target for Workday is set to $251.00. In the third quarter, Workday showed an EPS of $0.86, compared to $0.53 from the year-ago quarter. The stock has a 52-week-high of 248.75 and a 52-week-low of 107.75. At the end of the last trading period, Workday closed at $207.10. * With a current rating of Overweight, KeyBanc initiated coverage on Oracle Corp (NYSE: ORCL). The price target seems to have been set at $65.00 for Oracle. Oracle earned $0.93 in the first quarter, compared to $0.81 in the year-ago quarter. The current stock performance of Oracle shows a 52-week-high of 62.5999 and a 52-week-low of 39.71. Moreover, at the end of the last trading period, the closing price was at $56.11. * With a current rating of Overweight, KeyBanc initiated coverage on ServiceNow Inc (NYSE: NOW). The price target seems to have been set at $620.00 for ServiceNow. ServiceNow earned $1.21 in the third quarter, compared to $0.99 in the year-ago quarter. At the moment, the stock has a 52-week-high of 537.53 and a 52-week-low of 238.93. ServiceNow closed at $522.70 at the end of the last trading period. * KeyBanc initiated coverage on Microsoft Corp (NASDAQ: MSFT) with an Overweight rating. The price target for Microsoft is set to $250.00. For the first quarter, Microsoft had an EPS of $1.82, compared to year-ago quarter EPS of $1.38. The current stock performance of Microsoft shows a 52-week-high of 232.86 and a 52-week-low of 132.52. Moreover, at the end of the last trading period, the closing price was at $210.11. * With a current rating of Overweight, KeyBanc initiated coverage on Salesforce.com Inc (NYSE: CRM). The price target seems to have been set at $310.00 for Salesforce.com. For the second quarter, Salesforce.com had an EPS of $1.44, compared to year-ago quarter EPS of $0.66. The stock has a 52-week-high of 284.5 and a 52-week-low of 115.29. At the end of the last trading period, Salesforce.com closed at $257.58. * With a current rating of Buy, Goldman Sachs initiated coverage on Lufax Holding Ltd (NYSE: LU). The price target seems to have been set at $20.00 for Lufax Holding. The stock has a 52-week-high of 19.56 and a 52-week-low of 13.01. At the end of the last trading period, Lufax Holding closed at $15.07. * Evercore ISI Group initiated coverage on BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) with an Outperform rating. The price target for BioCryst Pharmaceuticals is set to $12.00. BioCryst Pharmaceuticals earned $0.26 in the third quarter, compared to $0.34 in the year-ago quarter. The stock has a 52-week-high of 6.2862 and a 52-week-low of 1.58. At the end of the last trading period, BioCryst Pharmaceuticals closed at $4.40. * For Datadog Inc (NASDAQ: DDOG), KeyBanc initiated coverage, by setting the current rating at Sector Weight. For the third quarter, Datadog had an EPS of $0.05, compared to year-ago quarter EPS of $0.00. At the moment, the stock has a 52-week-high of 118.13 and a 52-week-low of 28.88. Datadog closed at $91.04 at the end of the last trading period. * For Alteryx Inc (NYSE: AYX), KeyBanc initiated coverage, by setting the current rating at Sector Weight. In the third quarter, Alteryx showed an EPS of $0.39, compared to $0.24 from the year-ago quarter. The stock has a 52-week-high of 185.75 and a 52-week-low of 75.17. At the end of the last trading period, Alteryx closed at $113.05. * KeyBanc initiated coverage on Splunk Inc (NASDAQ: SPLK) with an Overweight rating. For the second quarter, Splunk had an EPS of $0.33, compared to year-ago quarter EPS of $0.67. The stock has a 52-week-high of 225.8944 and a 52-week-low of 93.92. At the end of the last trading period, Splunk closed at $198.11. * For Palo Alto Networks Inc (NYSE: PANW), KeyBanc initiated coverage, by setting the current rating at Overweight. Palo Alto Networks earned $1.62 in the first quarter, compared to $1.05 in the year-ago quarter. The current stock performance of Palo Alto Networks shows a 52-week-high of 296.71 and a 52-week-low of 125.47. Moreover, at the end of the last trading period, the closing price was at $296.12.See more from Benzinga * Click here for options trades from Benzinga * Understanding American Airlines Group's Unusual Options Activity * Analyzing Camping World Holdings's Unusual Options Activity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 5d ago
Curis, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 10, 2020 / Curis, Inc.
ACCESSWIRE · 11/10 19:45
Curis Announces Three Abstracts For CA-4948 Accepted For Presentation At 62nd American Society Of Hematology Annual Meeting And Exposition
Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc.
Benzinga · 11/04 18:31
Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that three abstracts for CA-4948, a small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH) which will be held virtually from December 5-8, 2020.
PR Newswire · 11/04 18:29
Curis Highlights Publication In ACS Medicinal Chemistry Letters Showcasing Targeted Potency And Ideal Pharmacologic Properties Of CA-4948 For Treatment Of Hematologic Malignancies
LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a
Benzinga · 10/21 12:08
Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a Trial in Progress abstract for CI-8993, a first-in-class monoclonal anti-VISTA antibody, has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which will be held virtually from November 9-14, 2020.
PR Newswire · 10/14 22:01
Curis Reports Trial In Progress Abstract For CI-8993 Monoclonal Anti-VISTA Antibody Accepted For Poster Presentation At Society For Immunotherapy Of Cancer Meeting Nov. 14
m
Benzinga · 10/14 21:02
MyoKardia, Eidos Therapeutics leads healthcare gainers, Xtant Medical Holdings, Curis among major losers
Gainers: MyoKardia (MYOK) +58%, Eidos Therapeutics (EIDX) +41%, Enlivex Therapeutics (ENLV) +25%, Humanigen (HGEN) +28%, Corvus Pharmaceuticals (CRVS) +26%.Losers: Xtant Medical Holdings (XTNT) -15%, Curis (CRIS) -7%, Immunome (IMNM) -6%, Novus Therapeutics (NVUS) -4%, Sintx Technologies (SINT) -4%.
Seekingalpha · 10/05 14:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRIS. Analyze the recent business situations of Curis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRIS stock price target is 4.750 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 24.19M
% Owned: 41.12%
Shares Outstanding: 58.82M
TypeInstitutionsShares
Increased
16
1.55M
New
19
932.74K
Decreased
9
1.88M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Martyn Greenacre
President/Chief Executive Officer/Director
James Dentzer
Chief Financial Officer
William Steinkrauss
Other
Robert Martell
Independent Director
Kenneth Kaitin
Independent Director
Lori Kunkel
Independent Director
Marc Rubin
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CRIS
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.